Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common cholesterol drug help fight ovarian cancer?

NCT ID NCT04457089

Disease control Sponsor: Marc Goodman Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested whether adding simvastatin, a common cholesterol-lowering drug, to standard chemotherapy could slow cancer progression in women with recurrent platinum-sensitive ovarian cancer. 18 participants took simvastatin alongside carboplatin and liposomal doxorubicin. The main goal was to see if patients could stick with the treatment, and researchers also tracked cancer markers and survival time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

18 people

The number who actually took part.

Started

Jan 2021

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment. * No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin. Exclusion Criteria: * Prior or current use of any statin medication * Current systemic use of medications known to interact with statins * Current use of any other investigational agents * Liver disease, active cirrhosis * Uncontrolled intercurrent illness * History of chronic myopathy * Prior cancer other than ovarian cancer or non-melanomatous skin cancers * Known active infection with HIV * Current excessive alcohol consumption (average alcohol consumption of more than 5 drinks per day) * Prior exposure to doxorubicin or liposomal doxorubicin * Hemoglobin A1C \>8.0%

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Platinum-sensitive ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Platinum-sensitive ovarian cancer Recurrent ovarian cancer

Contacts and locations

Locations

  • Cedars Sinai Medical Center

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.